Literature DB >> 24077247

Angiotensin-II induced hypertension and renovascular remodelling in tissue inhibitor of metalloproteinase 2 knockout mice.

Sathnur Pushpakumar1, Sourav Kundu, Tyranny Pryor, Srikanth Givvimani, Eleanor Lederer, Suresh C Tyagi, Utpal Sen.   

Abstract

BACKGROUND: Sustained hypertension induces renovascular remodelling by altering extracellular matrix (ECM) components. Matrix metalloproteinases (MMPs) are Zn-dependent enzymes that regulate ECM turnover in concert with their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). Increased MMP-2 and MMP-9 have been implicated in hypertensive complications; however, the contribution of individual MMPs/TIMPs in renal remodelling has not been fully elucidated. The purpose of this study was to determine the effect of TIMP2 deficiency and thus MMP-2 on angiotensin-II (Ang-II) induced renal remodelling.
METHOD: C57BL/6J (wild-type) and TIMP2 knockout mice were infused with Ang-II at 250 ng/kg per min for 4 weeks. Blood pressure was measured weekly and end-point laser Doppler flowmetry was done to assess cortical blood flow. Immunohistochemical staining was performed for collagen and elastin analyses. The activity of MMP-9 and MMP-2 was determined by Gelatin zymography.
RESULTS: Ang-II induced similar elevation in mean blood pressure in TIMP2 and wild-type mice. In TIMP2 mice, Ang-II treatment was associated with a greater reduction in renal cortical blood flow and barium angiography demonstrated decreased vascular density compared with Ang-II treated wild-type mice. Peri-glomerular and vascular collagen deposition was increased and elastin content was decreased causing increased wall-to-lumen ratio in TIMP2 mice compared with wild-type mice receiving Ang-II. Ang-II increased the expression and activity of MMP-9 predominantly in TIMP2 mice than in wild-type mice.
CONCLUSION: These results suggest that TIMP2 deficiency exacerbates renovascular remodelling in agonist-induced hypertension by a mechanism that may, in part, be attributed to increased activity of MMP-9.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24077247      PMCID: PMC4000563          DOI: 10.1097/HJH.0b013e3283649b33

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  49 in total

1.  Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.

Authors:  Anna Solini; Chiara Rossi; Eleonora Santini; Stephanie Madec; Antonio Salvati; Ele Ferrannini
Journal:  J Hypertens       Date:  2011-10       Impact factor: 4.844

2.  Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats.

Authors:  Mingyi Wang; Jing Zhang; Gaia Spinetti; Li-Qun Jiang; Robert Monticone; Di Zhao; Linda Cheng; Melissa Krawczyk; Mark Talan; Gianfranco Pintus; Edward G Lakatta
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 3.  Circulating matrix metalloproteinases and their inhibitors in hypertension.

Authors:  Vanessa Fontana; Pamela S Silva; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Clin Chim Acta       Date:  2012-01-08       Impact factor: 3.786

4.  Matrix metalloproteinases and small artery remodeling.

Authors:  Luis A Martinez-Lemus; Edgar Luis Galiñanes
Journal:  Drug Discov Today Dis Models       Date:  2011

5.  Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease.

Authors:  Edward R Smith; Laurie A Tomlinson; Martin L Ford; Lawrence P McMahon; Chakravarthi Rajkumar; Stephen G Holt
Journal:  Hypertension       Date:  2012-03-12       Impact factor: 10.190

Review 6.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

7.  Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.

Authors:  Vanessa Fontana; Pamela S Silva; Vanessa A Belo; Raquel C Antonio; Carla S Ceron; Celso Biagi; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-04-04       Impact factor: 4.080

8.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

9.  Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury.

Authors:  S Kim; K Ohta; A Hamaguchi; T Omura; T Yukimura; K Miura; Y Inada; T Wada; Y Ishimura; F Chatani
Journal:  Kidney Int       Date:  1994-11       Impact factor: 10.612

10.  Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.

Authors:  A A Geisterfer; M J Peach; G K Owens
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

View more
  19 in total

1.  Hydrogen sulfide alleviates hypertensive kidney dysfunction through an epigenetic mechanism.

Authors:  Gregory J Weber; Sathnur B Pushpakumar; Utpal Sen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-17       Impact factor: 4.733

2.  Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.

Authors:  Madhu V Singh; Michael Z Cicha; Sarah Nunez; David K Meyerholz; Mark W Chapleau; François M Abboud
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-22       Impact factor: 4.733

3.  MMP-9- and NMDA receptor-mediated mechanism of diabetic renovascular remodeling and kidney dysfunction: hydrogen sulfide is a key modulator.

Authors:  Sourav Kundu; Sathnur Pushpakumar; Utpal Sen
Journal:  Nitric Oxide       Date:  2015-02-07       Impact factor: 4.427

Review 4.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

Review 5.  Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator.

Authors:  Utpal Sen; Sathnur B Pushpakumar; Matthew A Amin; Suresh C Tyagi
Journal:  Nitric Oxide       Date:  2014-06-22       Impact factor: 4.427

6.  DNA hypermethylation in hyperhomocysteinemia contributes to abnormal extracellular matrix metabolism in the kidney.

Authors:  Sathnur Pushpakumar; Sourav Kundu; Nithya Narayanan; Utpal Sen
Journal:  FASEB J       Date:  2015-07-29       Impact factor: 5.191

7.  Epigenetic regulation of aortic remodeling in hyperhomocysteinemia.

Authors:  Nithya Narayanan; Sathnur Basappa Pushpakumar; Srikanth Givvimani; Sourav Kundu; Naira Metreveli; Dexter James; Adrienne P Bratcher; Suresh C Tyagi
Journal:  FASEB J       Date:  2014-04-16       Impact factor: 5.191

8.  Collagen receptor- and metalloproteinase-dependent hypertensive stress response in mesangial and glomerular endothelial cells.

Authors:  Suravi Majumder; Matthew Amin; Sathnur Pushpakumar; Utpal Sen
Journal:  Mol Cell Biochem       Date:  2020-01-07       Impact factor: 3.842

Review 9.  Reactive Oxygen Species: A Key Hallmark of Cardiovascular Disease.

Authors:  Nisha Panth; Keshav Raj Paudel; Kalpana Parajuli
Journal:  Adv Med       Date:  2016-09-28

Review 10.  Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases.

Authors:  Feng He; Li Zuo
Journal:  Int J Mol Sci       Date:  2015-11-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.